Statins

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

By

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Five things for pharma marketers to know: Wednesday, December 2, 2015

Five things for pharma marketers to know: Wednesday, December 2, 2015

By

Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

By

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.